Drug Profile

Dasatinib - Bristol-Myers Squibb

Alternative Names: BMS-354825; Sprycel

Latest Information Update: 24 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bristol-Myers Squibb
Developer Bristol-Myers Squibb; City of Hope National Medical Center; Dana-Farber Cancer Institute; Massachusetts General Hospital; Otsuka Pharmaceutical; Sarcoma Alliance for Research through Collaboration; University of Texas M. D. Anderson Cancer Center; Weill Cornell Medical College
Class Alcohols; Amides; Amines; Antineoplastics; Chlorobenzenes; Ethanolamines; Piperazines; Pyrimidines; Small molecules; Thiazoles
Mechanism of Action Bcr-Abl tyrosine kinase inhibitors; EphA2 receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto-oncogene protein c-kit inhibitors; Src-family kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
New Molecular Entity Yes

Marketed Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
Phase III Prostate cancer
Phase II Breast cancer; Cholangiocarcinoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Myeloproliferative disorders; Sarcoma
Phase I/II Glioblastoma; Non-Hodgkin's lymphoma; Solid tumours
No development reported Colorectal cancer; Leukaemia; Malignant melanoma; Malignant-mesothelioma; Multiple myeloma; Non-small cell lung cancer; Waldenstrom's macroglobulinaemia
Discontinued Pancreatic cancer; Scleroderma

27 Jan 2025 Bristol-Myers Squibb complete a phase II clinical trial in Chronic myeloid leukaemia (In adolescents, In children, Newly diagnosed) in US, Argentina, Australia, Brazil, Canada, France, Germany, India, Italy, South Korea, Mexico, the Netherlands, Romania, Russia, Singapore, South Africa, Spain, the United Kingdom (PO) (NCT00777036)
28 Nov 2024 No recent reports of development identified for phase-I development in Malignant-mesothelioma(Early-stage disease, First-line therapy, Mid-stage disease) in USA (PO, Tablet)
28 Nov 2024 No recent reports of development identified for phase-I development in Waldenstrom's macroglobulinaemia(Second-line therapy or greater) in USA (PO)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com